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Hematopoietic  stem  cells  (HSCs)  are  distin-
guished by their inherent capacity to perpetu-
ate  themselves  through  self-renewal  and  to 
generate multiple blood cell lineages through 
differentiation. To maintain a steady-state pool 
of self-renewing HSCs and prevent HSC ex-
haustion,  these  defining  properties  of  HSCs 
must be tightly regulated. Fine-tuning of stem 
cell properties requires stem cell–specific ex-
pression of their regulatory genes. To elucidate 
the stemness transcriptional profile, several gene 
expression microarray analyses have identified 
quite a few number of HSC-specific gene can-
didates (Ramalho-Santos et al., 2002; Akashi   
et al., 2003; Forsberg et al., 2010). However, 
most of the molecules established to be associ-
ated with the regulation of self-renewal capacity 
in HSCs are widely expressed in the hemato-
poietic system, and their mutations in genetic 
models are exclusively accompanied with other 
hematological abnormalities. Thus, a bona fide 
stem  cell–specific  regulator  of  their  function 
has  not  been  identified,  and  the  functional 
identification of HSCs based on their ability to 
self-renew remains difficult.
Ecotropic viral integration site 1 (Evi1) is an 
oncogenic transcription factor that belongs to 
the SET/PR domain protein family (Goyama and 
Kurokawa, 2009). We and others have reported 
that Evi1 accomplishes an important regulatory 
function  in  hematopoietic  stem/progenitor 
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Ecotropic viral integration site 1 (Evi1), a transcription factor of the SET/PR domain pro-
tein family, is essential for the maintenance of hematopoietic stem cells (HSCs) in mice and 
is overexpressed in several myeloid malignancies. Here, we generate reporter mice in which 
an internal ribosome entry site (IRES)-GFP cassette is knocked-in to the Evi1 locus. Using 
these mice, we find that Evi1 is predominantly expressed in long-term HSCs (LT-HSCs) in 
adult bone marrow, and in the hematopoietic stem/progenitor fraction in the aorta-
gonad-mesonephros, placenta, and fetal liver of embryos. In both fetal and adult hemato-
poietic systems, Evi1 expression marks cells with long-term multilineage repopulating 
activity. When combined with conventional HSC surface markers, sorting according to Evi1 
expression markedly enhances purification of cells with HSC activity. Evi1 heterozygosity 
leads to marked impairment of the self-renewal capacity of LT-HSCs, whereas overexpres-
sion of Evi1 suppresses differentiation and boosts self-renewal activity. Reintroduction of 
Evi1, but not Mds1-Evi1, rescues the HSC defects caused by Evi1 heterozygosity. Thus, in 
addition to documenting a specific relationship between Evi1 expression and HSC self-
renewal activity, these findings highlight the utility of Evi1-IRES-GFP reporter mice for the 
identification and sorting of functional HSCs.
© 2011 Kataoka et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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which suggests a distinctive relationship between Evi1 and 
HSC function. Consistent with this, heterozygosity of Evi1 
causes a striking reduction in the number of LT-HSCs, with 
a specific defect of self-renewal capacity caused by acceler-
ated differentiation. Our results point to a potential utility of 
an Evi1-GFP reporter mouse line for the functional identifi-
cation of HSCs based on their self-renewal activity, and a 
central role of Evi1 in regulating the homeostasis of HSCs.
RESULTS
Evi1 is predominantly expressed in LT-HSCs in adult BM
To elucidate Evi1 expression within the hematopoietic system, 
we have generated gene-targeted mice in which an internal 
ribosome entry site (IRES)-GFP cassette is knocked-in to the 
Evi1 locus by homologous recombination (Fig. 1 A). This 
knock-in allele functions in a bicistronic manner in that ex-
pression of both Evi1 and GFP is under the endogenous tran-
scriptional regulatory elements of the Evi1 gene, thus enabling 
us to track Evi1 expression on an individual cell basis. Appro-
priately targeted TT2 embryonic stem (ES) cell clones were 
identified by Southern blotting (Fig. 1 B). Mice heterozygous 
for the Evi1-IRES-GFP allele (Evi1+/GFP) were distinguished 
from WT mice by genotyping PCR (Fig. 1 C). 
Western blot analysis showed the presence of 
GFP protein and comparable expression of Evi1 
protein  in  embryonic  fibroblast  cells  from 
Evi1+/GFP  mice  compared  with  WT  mice   
(Fig. 1 D). Evi1+/GFP mice were phenotypi-
cally indistinguishable in survival, hematopoi-
etic cellularity, and lineage composition from 
WT  controls  (unpublished  data).  Initial  flow 
cytometric analysis of adult Evi1+/GFP mice re-
vealed a small, but discrete, population of GFP+ 
cells (0.15 ± 0.6%; Fig. 2 A), confirming the ex-
pression of the Evi1-IRES-GFP allele. To exam-
ine  whether  GFP  expression  levels  correlated 
with those of endogenous Evi1 mRNA expres-
sion, Evi1 expression of sorted GFP and GFP+ 
cells from BM of Evi1+/GFP mice was analyzed 
by  real-time  quantitative  PCR  (RQ-PCR). 
Evi1 mRNA was exclusively expressed in the 
GFP+ cells, and almost no expression was found 
in the GFP cells (Fig. 2 B), indicating that 
GFP expression in this mouse model faithfully 
marks cells with active Evi1 expression.
cells (HSPCs) during fetal and adult development. Evi1 
expression is limited to HSPCs in the embryonic and adult 
hematopoietic  systems.  HSCs  in  Evi1/  embryos  are 
markedly decreased in numbers with defective repopulating 
capacity (Yuasa et al., 2005). Moreover, conditional deletion 
of Evi1 in adult mice revealed that Evi1 is essential for the 
maintenance of HSCs, but is dispensable for lineage com-
mitment (Goyama et al., 2008). Besides the importance of 
Evi1 in normal hematopoiesis, dysregulation of Evi1 expres-
sion can have distinct oncogenic potential in various my-
eloid malignancies (Goyama and Kurokawa, 2009). Indeed, 
aberrant EVI1 expression defines a unique subset of acute 
myeloid leukemia (AML), and predicts adverse outcome in 
patients (Lugthart et al., 2008; Gröschel et al., 2010). Fur-
thermore, Evi1 overexpression in hematopoietic cells leads to 
myelodysplasia in a murine BM transplant model (Buonamici 
et al., 2004).
In this study, using newly generated Evi1-GFP reporter 
mice, we demonstrate that Evi1 is preferentially expressed in 
LT-HSCs, and its expression can mark in vivo long-term 
multilineage repopulating HSCs and improve the conven-
tional HSC isolation strategy in both adult BM and embryo, 
Figure 1.  Generation of Evi1-IRES-GFP knock-in 
mice. (A) The structure of murine Evi1 and the targeted 
Evi1-IRES-GFP locus is shown. RV, EcoRV; X, XbaI.  
(B) Southern blot analysis of genomic DNA isolated from 
WT ES cells (Evi1+/+) and two independent clones of tar-
geted ES cells (Evi1+/GFP). DNA was digested with XbaI 
(left) or EcoRV (right), and hybridized with the indicated 
probes. (C) Genotyping of Evi1+/GFP mice by PCR.  
(D) Western blot analysis for GFP and Evi1 in embryonic 
fibroblast cells from Evi1+/+ and Evi1+/GFP mice. -Actin 
was used as a loading control. ME, Mds1-Evi1.JEM Vol. 208, No. 12 
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Because LSK cells, a population which contains multi-
potent  progenitors  (MPPs),  short-term  HSCs  (ST-HSCs), 
and long-term HSCs (LT-HSCs), include both a GFP+ frac-
tion and a GFP fraction, we next resolved GFP expression 
within the LSK compartment for other markers characteristic 
of LT-HSCs. When LSK cells were subdivided according to 
CD34 and Flk-2 expression (Orford and Scadden, 2008), the 
Flk-2 CD34 LSK fraction, which is considered to contain 
most LT-HSC activity, had the highest expression of GFP, 
and its expression decreased with differentiation to hemato-
poietic progenitors (Fig. 2 E). In addition, further enrichment 
for LT-HSCs within the LSK fraction using SLAM family 
receptors (CD48 and CD150; Kiel et al., 2005) revealed   
that GFP+ cells were found in greatest abundance within 
CD48 CD150+ LSK cells, in which LT-HSCs are highly 
enriched. In contrast, GFP expression was substantially down-
regulated  in  CD48+  LSK  cells,  irrespective  of  CD150 
expression (Fig. 2 F). When we examined how GFP+ cells 
were distributed within the LSK fraction, GFP expression 
was highly enriched in the Flk-2 CD34 LSK or CD48  
CD150+  LSK  fractions  (Fig.  2,  G  and  H).  Therefore,   
these  results  indi-
cate that Evi1 is dy-
namically regulated 
within  HSPCs;  its   
Evi1 mRNA has been shown to be expressed at signifi-
cantly higher levels in HSPCs (Lin Sca-1+ c-kit+ [LSK]) 
and common lymphoid progenitors (CLPs) than in other 
hematopoietic  cells  (Yuasa  et  al.,  2005;  Chen  et  al.,   
2008). To gain insight into the biological function of Evi1 
through its cell type–specific expression pattern, the distri-
bution of GFP+ cells was examined in adult BM from Evi1+/
GFP mice. Beyond expectation, GFP expression was highly 
restricted to the LSK fraction (Fig. 2 A). To confirm stem/
progenitor-specific  expression  of  Evi1,  we  analyzed  the 
GFP fluorescence of various hematopoietic cell popula-
tions from BM and spleen of Evi1+/GFP mice. We found a 
heterogeneous expression of GFP in the LSK fraction, in 
which about half of the cells were GFP+ (Fig. 2, C and D). 
Conversely,  only  2.5%  of  common  myeloid  progenitors 
(CMPs)  expressed  GFP,  and  almost  no  expression  was 
found in granulocyte/monocyte progenitors (GMPs) and 
megakaryocyte/erythrocyte progenitors (MEPs; Fig. 2 C). 
In contrast to the previous study (Chen et al., 2008), GFP 
was not expressed in CLPs (Fig. 2 C). In addition, no GFP 
expression was observed in mature hematopoietic lineages 
or nonhematopoietic cells in BM (Fig. 2 C). Together, 
these  results  suggest  that  Evi1  is  uniquely  expressed  in 
HSPCs, but its expression is sharply down-regulated along 
with differentiation.
Figure 2.  Evi1 is predominantly ex-
pressed in LT-HSCs in adult BM. (A) FACS 
analysis of expression of lineage markers (Lin), 
c-kit, and Sca-1 on GFP+ cells in adult BM 
from Evi1+/GFP mice. Data are representative of 
three independent experiments. PI, propidium 
iodide; FSC, forward scatter. (B) RQ-PCR analy-
sis of the expression of Evi1 mRNA in sorted 
GFP or GFP+ cells from BM of Evi1+/GFP mice, 
presented relative to GAPDH expression (*, P < 
0.0001; n = 2). (C) Frequency of GFP+ cells in 
indicated BM subpopulation and in splenic  
T cells from Evi1+/GFP mice (n = 3–5). Meg, 
megakaryocyte; EC, endothelial cell. (D) FACS 
analysis of expression of GFP in LSK cells from 
Evi1+/+ and Evi1+/GFP mice. Data are represen-
tative of at least twenty independent experi-
ments. (E and F) Frequency of GFP+ cells in 
subpopulations of LSK cells divided using Flk-2  
and CD34 (E) or CD48 and CD150 (F) in 
Evi1+/GFP mice. (left) Representative plot is 
shown. (right) Bar graph represents mean ± 
SD (n = 3–4). (G-H) FACS analysis of expres-
sion of Flk-2 and CD34 (G) or CD48 and 
CD150 (H) on LSK GFP+ cells in BM from 
Evi1+/GFP mice. Data are representative of two 
independent experiments. (I) Frequency of  
Flk-2 CD34 LSK or CD48 CD150+ LSK cells 
in BM from Evi1+/+ and Evi1+/GFP mice (n = 3–5).   
(J) PB donor chimerism in CRAs, in which 2 × 
105 BM cells from Evi1+/+ and Evi1+/GFP mice 
(Ly5.1) were transplanted into lethally irradi-
ated recipients (Ly5.2) together with 2 × 105 
competitor BM cells (Ly5.2). Percentages of 
donor-derived cells (Ly5.1) in PB 16 wk after 
transplantation are shown (P = 0.12; n = 3). 
Data represent mean ± SD.2406 Evi1 expression marks long-term repopulating HSCs | Kataoka et al.
two populations, LSK GFP and LSK GFP+ cells were cul-
tured in serum-free medium containing stem cell factor (SCF) 
and thrombopoietin (TPO). After 3 d of culture, the propor-
tion  that  remained  in  the  LSK  fraction  was  significantly 
higher in LSK GFP+ cells than in LSK GFP cells (Fig. 3 B), 
suggesting that LSK GFP+ cells are more primitive HSCs. 
Next, to evaluate the differentiation potential of LSK GFP 
and LSK GFP+ cells, we performed colony-forming assays 
in vitro. Although both populations generated an equivalent 
number of myeloid colonies CFU-granulocyte/macrophage 
[CFU-GM]), LSK GFP+ cells gave rise to greater numbers 
of erythroid (burst-forming unit-erythrocyte [BFU-E]) and 
multipotential (CFU-granulocyte/erythrocyte/macrophage/
megakaryocyte  [CFU-GEMM])  colonies  than  LSK  GFP 
cells (Fig. 3 C). These data suggest that Evi1 expression cor-
relates with multipotent differentiation capacity. In addition, 
to assess the colony-forming capacity at the clonal level, 
single LSK GFP and LSK GFP+ cells were cultured in   
serum-free medium. LSK GFP cells formed detectable 
colonies at a frequency comparable to LSK GFP+ cells, but 
generated smaller numbers of highly proliferative colonies 
(>300 cells; Fig. 3 D), indicating that the LSK GFP+ fraction 
comprises a higher proportion of HSPCs with enhanced pro-
liferative capacity.
Our observations suggested that Evi1 reporter activity is 
down-regulated as HSCs differentiate. To examine this issue, 
we forced LSK GFP+ cells to differentiate in vitro in response to 
SCF, TPO, IL-3, and IL-6. These LSK GFP+ cells predomi-
nantly generated GFP cells (Fig. 3 E). After culture, the major-
ity of cells that had become GFP lost the LSK phenotype, 
whereas most cells that remained in GFP+ continued to express 
expression is predominantly enriched in LT-HSCs and rapidly 
extinguished during early stages of lineage commitment.
To reinforce Evi1-IRES-GFP knock-in mice as a faithful 
tool for investigating HSCs, we assessed the number and func-
tion of LT-HSCs in BM from Evi1+/GFP mice. Flow cytometric 
analysis revealed that the frequencies of Flk-2 CD34 
LSK or CD48 CD150+ LSK cells were comparable between 
Evi1+/+ and Evi1+/GFP mice (Fig. 2 I). In addition, a com-
petitive repopulation assay (CRA) showed that Evi1+/GFP BM 
cells exhibited slightly less, but not significantly different, long-
term reconstitution capacity (Fig. 2 J), indicating that the 
number and function of HSCs in Evi1+/GFP mice are similar to 
WT controls.
Evi1 expression represents a functionally distinct  
population that remains in an undifferentiated  
and quiescent state within HSPCs
As only a subset of LSK cells expressed GFP in Evi1+/GFP 
mice, we hypothesized that Evi1 expression functionally di-
vides the LSK population and marks a more undifferentiated 
and quiescent state with multipotent differentiation proper-
ties in this population. To test this idea, we separated the LSK 
population into LSK GFP and LSK GFP+ cells and com-
pared their biological functions. Initially, we confirmed that 
LSK GFP+ cells had a much higher level of Evi1 transcripts 
than LSK GFP cells by RQ-PCR analysis (Fig. 3 A). Inter-
estingly, despite the negative GFP expression, LSK GFP 
cells expressed Evi1 mRNA at a higher level compared with 
CMPs and GMPs (Fig. 3 A), which also suggests that Evi1 
expression is inversely proportional to the differentiation status. 
To achieve an estimate of the differentiation stage of these 
Figure 3.  Evi1 expression represents a 
functionally distinct population that re-
mains in an undifferentiated and quies-
cent state within HSPCs. (A) RQ-PCR 
analysis of the expression of Evi1 mRNA in 
sorted GMPs, CMPs, LSK GFP cells, and LSK 
GFP+ cells from Evi1+/GFP mice, presented rela-
tive to GAPDH expression (n = 2). (B) LSK 
GFP and LSK GFP+ cells were cultured in 
serum-free medium with 20 ng/ml SCF and 
20 ng/ml TPO for 3 d, and the percentage of 
the remaining LSK fraction was analyzed  
(*, P < 0.001; n = 3). (C) Numbers of CFU-GM, 
CFU-GEMM, and BFU-E colonies derived from 
100 sorted LSK GFP and LSK GFP+ cells  
(*, P < 0.05; n = 3). (D) Single LSK GFP and 
LSK GFP+ cells from Evi1+/GFP mice were clone-
sorted and cultured in serum-free medium. 
After 14 d of culture, cell numbers in each 
colony were analyzed. Their relative distribu-
tion is shown (*, P < 0.05; n = 192 clones 
from 2 independent experiments). (E) LSK GFP+ cells were cultured in medium containing 10% serum with 50 ng/ml SCF, 50 ng/ml TPO, 10 ng/ml IL-3, and 
10 ng/ml IL-6 for 5 d, and the percentage of the remaining GFP+ fraction were analyzed. Data are representative of four independent experiments. (F) The 
percentages of the remaining LSK fraction in GFP and GFP+ cells after culture were analyzed (*, P < 0.0001; n = 4). (G) Numbers of CFU-GM, CFU-GEMM, 
and BFU-E colonies derived from 200 GFP and GFP+ cells were analyzed (*, P < 0.0001; n = 4). (H) Cell cycle status of LSK GFP and LSK GFP+ cells from 
Evi1+/GFP mice, analyzed by Hoechst 33342 and pyronin Y staining (*, P < 0.05; **, P < 0.005; ***, P < 0.0005, n = 3). Data represent mean ± SD.JEM Vol. 208, No. 12 
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a functionally distinct population that remains in an undiffer-
entiated and quiescent state.
Evi1 expression marks in vivo long-term multilineage 
repopulating HSCs in adult BM
Based on the aforementioned data, we hypothesized that 
Evi1  expression  would  have  the  potential  to  effectively 
mark long-term multilineage repopulating HSCs. To ex-
amine this issue, we performed a CRA, in which 500 puri-
fied LSK GFP or LSK GFP+ cells were transplanted with 
2 × 105 competitor BM cells into lethally irradiated recipi-
ents (Fig. S1 A). At 16 wk after transplantation, flow cyto-
metric analysis of donor-derived cells revealed long-term 
reconstitution in all recipients transplanted with LSK GFP+ 
cells (Fig. 4 A). Moreover, LSK GFP+ cells displayed multi-
lineage potential with robust contribution to myeloid, B, 
and T cells in peripheral blood (PB) as well as the LSK 
the LSK phenotype (Fig. 3 F), indicating that loss of GFP corre-
lates with phenotypic differentiation. To confirm the differential 
phenotype of the GFP and GFP+ cells after culture reflected 
their functional status, we compared their ability to form colo-
nies in methylcellulose. GFP+ cells yielded significantly more 
colonies than GFP cells (Fig. 3 G), suggesting that functionally 
primitive  HSCs  predominantly  reside  in  the  GFP+  fraction. 
Collectively, these data indicate that in vitro culture of LSK 
GFP+ cells leads to generation of GFP cells that are more dif-
ferentiated, and lend credence to the use of GFP as a fluorescent 
sensor for the differentiation state of hematopoietic cells.
To determine the cell-cycle distribution of LSK GFP 
and LSK GFP+ cells, we performed Hoechst 33342 and py-
ronin Y staining, which revealed that the majority of LSK 
GFP+ cells were in G0 phase, whereas a significant proportion 
of LSK GFP cells were actively cycling (Fig. 3 H). These 
data indicate that, within HSPCs, Evi1 expression represents 
Figure 4.  Evi1 expression marks in vivo 
long-term multilineage repopulating HSCs 
in adult BM. (A and B) PB donor chimerism in 
CRAs, in which 500 LSK GFP or LSK GFP+ cells 
sorted from Evi1+/GFP mice (Ly5.2) were trans-
planted into lethally irradiated recipients 
(Ly5.1) together with 2 × 105 competitor BM 
cells (Ly5.1 × Ly5.2). (A) Percentages of donor-
derived cells (Ly5.2) in PB after transplantation 
are shown. Each dot indicates an individual 
recipient mouse (*, P < 0.005; n = 6–7 from 2 
independent experiments). (B) Percentages of 
donor-derived cells (Ly5.2) in myeloid, B, and  
T cells of PB and LSK cells of BM 16 wk after 
transplantation. Recipient mice in experiment 1 
were used for the analysis of BM (*, P < 0.01;  
n = 6–7 for PB and n = 3 for BM). (C) Percent-
ages of donor-derived cells (Ly5.2) in PB of 
secondary recipient mice (Ly5.1) 16 wk after 
transplantation. Recipient mice in experiment 
1 were used for secondary transplantation  
(*, P < 0.0001, n = 3). (D–K) PB donor chime-
rism in CRAs, in which 100 CD48 CD150+ LSK 
GFP or CD48 CD150+ LSK GFP+ cells (D and 
E; n = 7–8), or 500 CD48+ CD150 LSK GFP 
or CD48+ CD150 LSK GFP+ cells (F and G; n = 7),  
or 100 Flk-2 CD34 LSK GFP or Flk-2 
CD34 LSK GFP+ cells (H and I; n = 3–4), or 
500 Flk-2+ CD34+ LSK GFP or Flk-2+ CD34+ 
LSK GFP+ cells (J and K; n = 3–4) sorted from 
Evi1+/GFP mice (Ly5.1) were transplanted into 
lethally irradiated recipients (Ly5.2) together 
with 2 × 105 competitor BM cells (Ly5.2).  
(D, F, H, and J) Percentages of donor-derived 
cells (Ly5.1) in total (left) and myeloid cells 
(right) of PB after transplantation are shown. 
Each dot indicates an individual recipient mouse  
(*, P < 0.05; **, P < 0.005; ***, P < 0.0005).  
(E, G, I, and K) Percentages of donor-derived 
cells (Ly5.1) in myeloid, B, and T cells of PB  
16 wk after transplantation (*, P < 0.05;  
**, P < 0.005). Data represent mean ± SD.2408 Evi1 expression marks long-term repopulating HSCs | Kataoka et al.
GFP cells provided only a transient reconstitution, CD48+ 
CD150 LSK GFP+ cells showed declining, but sustained en-
graftment 16 wk after transplantation (Fig. 4 F). In contrast   
to CD48 CD150+ LSK GFP+ cells, CD48+ CD150 LSK 
GFP+ cells mediated faint myeloid but superior lymphoid re-
constitution (Fig. 4, F and G). Although it is controversial 
whether CD48+ CD150 LSK cells are transiently reconsti-
tuting MPPs/ST-HSCs or lymphoid-biased LT-HSCs with 
limited long-term engraftment and strong predominance of 
lymphoid reconstitution (Kiel et al., 2005; Weksberg et al., 
2008; Grassinger et al., 2010), Evi1-expressing cells possess 
higher repopulating capacity within this fraction. When we 
subfractionated the LSK fraction according to CD34 and 
Flk-2 expression, and compared the repopulating capacity of 
GFP and GFP+ cells within these subsets (Fig. S1 C), we ob-
tained similar results to the aforementioned findings using 
SLAM markers (Fig. 4, H–K). These data reveal that, irrespec-
tive of the combination of HSC surface markers used, GFP+ 
cells are the exclusive reservoir of HSC activity, with no re-
constitution ability being observed in GFP cells within the 
LT-HSC compartment. Altogether, our results demonstrate 
that Evi1 expression can further augment the conventional 
HSC purification strategy, and suggest that Evi1-IRES-GFP 
knock-in mice allow us to functionally identify HSCs on the 
ground of self-renewal capacity.
fraction in BM (Fig. 4 B). In contrast, LSK GFP cells yielded 
an almost total inability to generate long-term chimerism 
(Fig. 4, A and B), which suggests that this population is de-
void of self-renewal activity. To confirm the in vivo repopu-
lating capacity of LSK GFP+ cells, we performed secondary 
transplantation.  Similarly,  LSK  GFP+  cells  showed  re-
markable  long-term  reconstitution,  whereas  LSK  GFP 
cells consistently failed to produce detectable donor-derived 
cells (Fig. 4 C), demonstrating that in vivo long-term multi-
lineage repopulating cells are exclusively enriched in the 
LSK GFP+ fraction in adult BM.
To further refine our analysis designating Evi1 expression 
as a robust and reliable HSC marker, we compared the re-
populating capacity of GFP and GFP+ cells within the 
CD48 CD150+ LSK fraction, which is enriched for LT-HSCs 
(Fig. S1 B). Intriguingly, CD48 CD150+ LSK GFP+ cells 
exhibited long-term multilineage reconstitution, whereas no 
engraftment was observed in recipients of CD48 CD150+ 
LSK GFP cells (Fig. 4, D and E), suggesting that long-term 
repopulating HSCs predominantly reside in the GFP+ frac-
tion even within the highly subfractionated LT-HSC fraction. 
We  then  examined  whether  Evi1  expression  is  associated 
with repopulating capacity in the CD48+ CD150 LSK frac-
tion, which is enriched for ST-HSCs/MPPs with limited self-
renewal activity (Fig. S1 B). Although CD48+ CD150 LSK 
Figure 5.  Evi1 expression marks in vivo 
long-term multilineage repopulating HSCs 
in embryo. (A–C) Frequency of GFP+ cells in 
each subpopulation of E10.5 AGM (A; n = 5) 
or E12.5 placenta (B; n = 3) or E14.5 FL (C; n = 
5) from Evi1+/GFP embryos. (D–F) FACS analy-
sis of expression of CD34 and c-kit on CD45+ 
GFP+ cells from E10.5 AGM (D) or CD34, c-kit, 
and CD48 on GFP+ cells from E12.5 placenta 
(E) or Lin, Mac-1, Sca-1, and CD48 on GFP+ 
cells from E14.5 FL (F) in Evi1+/GFP embryos. 
Data are representative of 2 to 10 indepen-
dent experiments. (G and H) Numbers of  
CFU-GM, CFU-GEMM, and BFU-E colonies de-
rived from 100 CD45+ GFP and CD45+ GFP+ 
cells sorted from E10.5 AGM (G; n = 3), or 100 
CD34+ c-kit+ CD48 GFP and CD34+ c-kit+ 
CD48 GFP+ cells sorted from E12.5 placenta 
(H; n = 3) in Evi1+/GFP embryos (*, P < 0.05;  
**, P < 0.0005). (I) PB donor chimerism in 
CRAs, in which 500 CD34+ c-kit+ CD48 GFP 
or CD34+ c-kit+ CD48 GFP+ cells sorted from 
E12.5 placenta of Evi1+/GFP embryos (Ly5.1 × 
Ly5.2) were transplanted into lethally irradi-
ated recipients (Ly5.2) together with 2 × 105 
competitor BM cells (Ly5.2). Percentages of 
donor-derived cells (Ly5.1 × Ly5.2) in PB after 
transplantation are shown. Each dot indicates 
an individual recipient mouse (*, P < 0.05;  
**, P < 0.005; n = 4–6). (J) PB donor chimerism 
in CRAs, in which 500 MSL GFP or MSL GFP+ cells sorted from E14.5 FL of Evi1+/GFP embryos (Ly5.2) were transplanted into lethally irradiated recipients 
(Ly5.1 × Ly5.2) together with 2 × 105 competitor BM cells (Ly5.1 × Ly5.2). Percentages of donor-derived cells (Ly5.2) in PB weeks after transplantation are 
shown. Each dot indicates an individual recipient mouse (*, P < 0.05; n = 4). Data represent mean ± SD.JEM Vol. 208, No. 12 
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CD45+ GFP+ cells contained almost all colony-forming 
cells, with few detectable hematopoietic colonies in CD45+ 
GFP cells (Fig. 5 G). In the same manner, within the CD34+ 
c-kit+ CD48 fraction from E12.5 placenta of Evi1+/GFP 
embryos, colony-forming activity was exclusively present 
in GFP+ cells, regardless of colony type (Fig. 5 H). These 
data  suggest  that  clonogenic  hematopoietic  progenitors 
predominantly  reside  in  the  Evi1-expressing  fraction  in   
fetal hematopoiesis.
To examine whether Evi1 expression would have the 
potential to effectively mark long-term repopulating HSCs 
in embryo, we performed a CRA using sorted CD34+ c-kit+ 
CD48 GFP and CD34+ c-kit+ CD48 GFP+ cells from 
E12.5 placenta of Evi1+/GFP embryos (Fig. S2 A). It was 
obvious that CD34+ c-kit+ CD48 GFP+ cells contributed 
to  the  long-term  reconstitution  of  irradiated  recipients, 
whereas donor chimerism was almost undetectable in mice 
transplanted with CD34+ c-kit+ CD48 GFP cells (Fig. 5 I), 
which is in agreement with the results obtained with their 
adult counterparts. To further assess whether Evi1 expres-
sion can enrich long-term repopulating HSCs in embryo, we 
performed  a  CRA  using  purified  MSL  GFP  and  MSL 
GFP+ cells from E14.5 FL (Fig. S2 B). Along with cells in 
E12.5  placenta,  MSL  GFP+  cells  gave  rise  to  long-term 
multilineage  reconstitution,  whereas  no  engraftment  was 
observed in recipients of MSL GFP cells (Fig. 5 J). These 
results indicate that fetal HSCs with active Evi1 transcrip-
tion  exclusively  harbor  stem  cell  activity.  Collectively,   
despite the functional differences between fetal and adult 
HSCs, Evi1 expression marks long-term multilineage re-
populating HSCs throughout ontogeny, suggesting a specific 
relationship  between  Evi1  expression  and  HSC  self-re-
newal capacity.
Evi1 expression marks in vivo long-term multilineage 
repopulating HSCs in embryo
The formation of blood cells begins in the yolk sac of the 
embryo,  and  then  shifts  to  the  aorta-gonad-mesonephros 
(AGM) region, and then sequentially to the placenta, fetal 
liver (FL), and adult BM. There are several major phenotypic 
and functional differences between fetal and adult HSCs in 
surface marker profile, cell cycle status, self-renewal poten-
tial,  gene  expression  profile,  and  regulatory  mechanism 
(Mikkola and Orkin, 2006; Orkin and Zon, 2008). Fetal 
HSCs, in particular, divide rapidly and undergo massive ex-
pansion, whereas adult HSCs are mostly quiescent (Bowie 
et al., 2006). It is known that Evi1 is highly expressed in the 
yolk  sac,  paraaortic  splanchnopleura,  and  HSPCs  (CD45+ 
CD34+ c-kit+) in early embryo (Yuasa et al., 2005). There-
fore, we sought to determine whether Evi1 expression can 
mark fetal HSCs despite their distinct features from adult 
HSCs, and thus analyzed the expression pattern of GFP in 
Evi1+/GFP embryos. As expected, GFP expression was highly 
restricted to HSPCs in the embryonic tissues; CD45+ CD34+ 
c-kit+ cells in embryonic day 10.5 (E10.5) AGM, CD34+  
c-kit+ CD48 cells in E12.5 placenta, and Mac-1+ Sca-1+ Lin 
(MSL) CD48 cells in E14.5 FL (Fig. 5, A-C; Takakura   
et al., 2000; Kim et al., 2006; McKinney-Freeman et al., 
2009). When the distribution of GFP+ cells in the fetal hema-
topoietic system was analyzed, most GFP+ cells exhibited the 
HSPC-specific marker profile in all embryonic tissues exam-
ined (Fig. 5, D–F), indicating the predominant expression of 
Evi1 in HSPCs during fetal hematopoiesis.
To determine whether Evi1 expression is associated with 
hematopoietic  activity  in  the  embryonic  tissues,  we  per-
formed colony-forming assays in vitro using CD45+ GFP 
and CD45+ GFP+ cells from E10.5 AGM, and found that 
Figure 6.  Evi1 heterozygosity leads to an 
almost complete loss of LT-HSCs in a cell-
autonomous manner. (A) FACS analysis of 
expression of Flk-2 and CD34 or CD48 and 
CD150 on LSK cells in BM from Evi1+/+ and 
Evi1+/ mice. Data are representative of at 
least three independent experiments. (B) Fre-
quency of myeloid (Lin Sca-1 c-kit+) and 
lymphoid progenitors (CLPs) in BM from 
Evi1+/+ and Evi1+/ mice (n = 3). (C) Frequency 
of Flk-2+ CD34+, Flk-2 CD34+, and Flk-2 
CD34 subsets within LSK cells in BM from 
Evi1+/+ and Evi1+/ mice (*, P < 0.0001; n = 8). 
(D) Frequency of CD48+ CD150, CD48+ 
CD150+, CD48 CD150, and CD48 CD150+ 
subsets within LSK cells in BM from Evi1+/+ 
and Evi1+/ mice (*, P < 0.01; n = 3). (E) Recip-
rocal transplantation assay was performed by 
transplantation of 2 × 105 WT BM cells (Ly5.1) 
into lethally irradiated Evi1+/+ or Evi1+/ mice 
(Ly5.2). Frequency of Flk-2 CD34 LSK or 
CD48 CD150+ LSK cells in BM of recipients 
16 wk after transplantation is shown (n = 4). 
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repopulating capacity of purified CD34+ LSK cells using a 
CRA. At 2 wk after transplantation, we detected comparable 
frequencies of Evi1+/+ and Evi1+/ CD34+ LSK cell–derived 
myeloid and B cells (Fig. 7 C), suggesting that heterozygosity 
of Evi1 does not affect the engraftment and differentiation 
potential of ST-HSCs/MPPs in vivo. However, at later time 
points in the experiment, we found a moderate but significant 
decline in the percentage of donor-derived cells from Evi1+/ 
mice (Fig. 7 D). These data indicate that heterozygosity of 
Evi1 attenuates the self-renewal capacity of ST-HSCs/MPPs, 
but is not accompanied by any specific differentiation defects 
in them.
To assess whether Evi1 is required for the functions of 
LT-HSCs, we compared the self-renewal and proliferation 
capacity of Evi1+/+ and Evi1+/ Flk-2 CD34 LSK cells 
when  cultured  in  serum-free  medium.  Evi1+/  Flk-2 
CD34 LSK cells showed comparable proliferation with WT 
cells for the first week of culture, but thereafter they exhib-
ited pronouncedly impaired growth (Fig. 7 E). After incuba-
tion,  a  significantly  lower  proportion  of  cultured  Evi1+/ 
Flk-2 CD34 LSK cells remained in the LSK fraction than 
those from Evi1+/+ mice (Fig. 7 F). In addition, we observed 
a prominent reduction of hematopoietic colonies contained 
in cultured Evi1+/ Flk-2 CD34 LSK cells (Fig. 7 G). 
Besides, most of the colonies generated from cultured Evi1+/ 
Flk-2 CD34 LSK cells consisted of only CFU-GM. These 
data indicate that heterozygosity of Evi1 results in accelerated 
loss of HSPCs, leading to the inefficient expansion of their 
progeny. To evaluate the colony-forming capacity at the 
single cell level, Evi1+/+ and Evi1+/ Flk-2 CD34 LSK 
cells were clonally sorted and cultured in serum-free me-
dium. Evi1 heterozygosity diminished the colony-forming 
efficiency of clone-sorted Flk-2 CD34 LSK cells, and sin-
gle Evi1+/ Flk-2 CD34 LSK cells generated smaller colo-
nies compared with control cells (Fig. 7 H), which indicates 
that the disruption of Evi1 gene not only decreases the num-
ber of clonogenic HSCs but also impairs the functional out-
put per cell.
To assess the repopulating capacity of Evi1+/ LT-HSCs 
in vivo, we performed a CRA using purified Flk-2 CD34 
LSK cells from Evi1+/+ and Evi1+/ mice. Notably, Evi1+/ 
Flk-2 CD34 LSK cells were almost unable to efficiently 
repopulate all mature lineages as well as stem and progenitor 
cells 16 wk after transplantation (Fig. 7, I and J), suggesting 
that LT-HSC function is critically dependent on Evi1 gene 
dosage. In a noncompetitive setting, although recipients of 
Evi1+/+ and Evi1+/ Flk-2 CD34 LSK cells had similar 
survival after transplantation (not depicted), Evi1+/ Flk-2 
CD34 LSK cells showed impaired engraftment (Fig. 7 K), 
suggesting that Evi1+/ HSCs were outcompeted by residual 
host  HSCs.  However,  some  of  those  recipients  exhibited 
long-term multilineage reconstitution (Fig. 7 K and not 
depicted), confirming that the multipotent differentiation 
capacity is not abrogated in Evi1+/ mice. To further explore 
the competitive disadvantage of Evi1+/ HSCs, we transplanted 
WT BM cells into unirradiated Evi1+/+ or Evi1+/ mice.   
Evi1 heterozygosity leads to an almost complete loss  
of LT-HSCs in a cell-autonomous manner
The aforementioned observations led us to predict that Evi1 
plays a functional role specifically in LT-HSCs. To clarify 
this issue, we analyzed heterozygous Evi1 KO mice (Evi1+/). 
We previously showed that heterozygosity of Evi1 leads to 
decreased numbers of LSK and CD34 LSK cells, as well as 
impaired  long-term  repopulating  activity  (Goyama  et  al., 
2008). In the current study, although Flk-2+ CD34+ and Flk-2 
CD34+  LSK  cells  were  moderately  decreased,  Flk-2 
CD34 LSK cells from Evi1+/ mice exhibited a marked re-
duction in frequency compared with WT controls (Fig. 6,   
A and C). Likewise, when LSK cells were subdivided according 
to SLAM markers, we observed substantial decreases in 
CD48 CD150 and CD48 CD150+ LSK subsets (Fig. 6, 
A  and  D).  Therefore,  the  number  of  each  subpopulation 
within the LSK fraction in Evi1+/ mice was declined in pro-
portion to their expression level of Evi1, indicating that Evi1 
has a dominating effect on the maintenance of LT-HSCs. In 
contrast, there were no significant differences in BM cellular-
ity and the frequencies of lymphoid and myeloid progenitors, 
and mature blood cells between Evi1+/+ and Evi1+/ mice 
(Fig. 6 B and not depicted), indicating that the differentiation 
potential to all mature lineages and committed progenitors is 
normal in Evi1+/ mice. Collectively, these observations sug-
gest that Evi1 serves as a specific regulator in the earliest stage 
of adult hematopoietic development.
To exclude the possibility that a defect of BM micro-
environment could be responsible for the observed hematopoi-
etic abnormalities in Evi1+/ mice, we performed reciprocal 
transplantation experiments, in which WT BM cells were 
transplanted into lethally irradiated Evi1+/+ or Evi1+/ mice. At 
16 wk after transplantation, flow cytometric analysis showed 
no differences in the percentages of Flk-2 CD34 LSK or 
CD48 CD150+ LSK cells in both groups of recipient mice 
(Fig. 6 E), demonstrating that the profound loss of LT-HSCs in 
Evi1+/ mice is attributed to cell-intrinsic mechanisms.
Evi1 heterozygosity causes specific abrogation  
of self-renewal capacity in ST- and LT-HSCs
To further characterize which subpopulation in HSPCs is 
most dependent on Evi1, we purified CD34+ and Flk-2 
CD34 LSK cells from Evi1+/+ and Evi1+/ mice and com-
pared their differentiation and self-renewal capacity in vitro 
and in vivo. First, to assess the effect of Evi1 heterozygosity 
on the biological functions of ST-HSCs/MPPs, we per-
formed  colony-forming  assays  in  vitro  using  Evi1+/+  and 
Evi1+/ CD34+ LSK cells, which demonstrated no significant 
differences in the number and type of colonies (Fig. 7 A). 
Similarly, we found the capacity of Evi1+/ CD34+ LSK cells 
to  form  colonies  in  the  spleen  11  d  after  transplantation 
(CFU-spleen [CFU-S]) was also equivalent to that of WT 
littermates (Fig. 7 B), indicating Evi1 is dispensable for the 
regulation of the differentiation and proliferation capacity in 
ST-HSCs/MPPs. Moreover, to investigate the self-renewal 
ability of ST-HSCs/MPPs in vivo, we evaluated the short-term JEM Vol. 208, No. 12 
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Figure 7.  Evi1 heterozygosity causes specific abrogation of self-renewal capacity in ST- and LT-HSCs. (A) Numbers of CFU-GM, CFU-
GEMM, and BFU-E colonies derived from 100 sorted Evi1+/+ and Evi1+/ CD34+ LSK cells (n = 3). (B) Appearance and number of CFU-S colonies in 
the spleen 11 d after injection of 100 sorted Evi1+/+ or Evi1+/ CD34+ LSK cells into lethally irradiated recipients. (left) Representative appearance 
is shown. (right) Data are shown as a dot plot and each bar represents mean (n = 15–16 from 3 independent experiments). (C and D) Short-term 
in vivo repopulating assay, in which 500 sorted Evi1+/+ or Evi1+/ CD34+ LSK cells (Ly5.2) were transplanted into lethally irradiated recipients 
(Ly5.1) together with 2 × 105 competitor BM cells (Ly5.1). (C) Percentages of donor-derived myeloid and B cells (Ly5.2) in PB 2 wk after transplan-
tation are shown (n = 3). (D) Short-term kinetics of the percentages of donor-derived cells (Ly5.2) in PB. Each dot indicates an individual recipient 
mouse (*, P < 0.05; n = 3). (E) Proliferation of 1,000 sorted Evi1+/+ and Evi1+/ Flk-2 CD34 LSK cells cultured in serum-free medium supple-
mented with 20 ng/ml SCF and 20 ng/ml TPO for 14 d (*, P < 0.01; ** P < 0.001; n = 3–4). (F) After 7 d of culture, the percentage of the remaining 
LSK fraction in cultured Evi1+/+ and Evi1+/ Flk-2 CD34 LSK cells was analyzed (*, P < 0.005; n = 3). (G) In vitro colony-forming assay was per-
formed to assess the numbers of CFU-GM, CFU-GEMM, and BFU-E colonies after 1,000 Evi1+/+ and Evi1+/ Flk-2 CD34 LSK cells were cultured 
for 14 d (*, P < 0.01; ** P < 0.001; n = 3–4). (H) Single Evi1+/+ and Evi1+/ Flk-2 CD34 LSK cells were clone-sorted and cultured in serum-free 
medium. After 14 d of culture, cell numbers in each colony were analyzed. Their relative distribution is shown (*, P < 0.0001; n = 192 clones from 
2 independent experiments). (I–J) Long-term in vivo repopulating assay, in which 200 sorted Evi1+/+ or Evi1+/ Flk-2 CD34 LSK cells (Ly5.2) were 
transplanted into lethally irradiated recipients (Ly5.1) together with 2 × 105 competitor BM cells (Ly5.1). (I) Percentages of donor-derived cells 
(Ly5.2) in PB after transplantation are shown. Each dot indicates an individual recipient mouse (*, P < 0.0001, n = 5–6). (J) Percentages of donor-
derived cells (Ly5.2) in myeloid, B, and T cells of PB and LSK cells of BM 16 wk after transplantation (*, P < 0.001; ** P < 0.0001; n = 5–6 for PB 
and n = 3 for BM). (K) Noncompetitive repopulating assay, in which 200 sorted Evi1+/+ or Evi1+/ Flk-2 CD34 LSK cells (Ly5.2) were transplanted 
into lethally irradiated recipients (Ly5.1) without competitor. Percentages of donor-derived cells (Ly5.2) in PB of recipient mice that survived  
12 wk after transplantation are shown (*, P < 0.05, n = 4–6). (L) Reciprocal transplantation assay was performed by transplantation of 2 × 105  
WT BM cells (Ly5.1) into unirradiated Evi1+/+ or Evi1+/ mice (Ly5.2). Percentages of donor-derived cells (Ly5.1) in PB 16 wk after transplantation 
are shown (n = 6–8). Data represent mean ± SD.2412 Evi1 expression marks long-term repopulating HSCs | Kataoka et al.
on the hematopoietic system than Evi1 and acts in part by 
maintaining HSC quiescence through up-regulation of Cdkn1c 
transcription (Zhang et al., 2011), Evi1 and ME may exert 
their functions in regulating hematopoiesis at different stages 
and by different mechanisms.
DISCUSSION
In this study, we show that the amount of Evi1 transcript can 
be indicative of an undifferentiated state with multipotent 
differentiation capacity within HSPCs. In both the fetal and 
adult hematopoietic systems, Evi1 expression can mark long-
term multilineage repopulating HSCs, and enhance HSC puri-
fication with a combination of other surface markers, suggesting 
a specific relationship between HSC activity and Evi1 ex-
pression throughout ontogeny. This stem cell-specific ex-
pression pattern of Evi1 allows us to functionally identify 
self-renewing  HSCs  by  using  Evi1-IRES-GFP  knock-in 
mice, and suggests the relevance of Evi1 in fine-tuning of 
stem cell properties. Indeed, we provide the genetic evidence 
confirming that Evi1 has a predominant effect on LT-HSCs 
by specifically regulating their self-renewal capacity.
The prospective isolation of HSCs is the most important 
step to dissect their function. The strategy commonly used 
for HSC isolation is purification based on the expression of a 
combination of cell surface markers. However, some of these 
parameters differ between strains of mice, change dramatically 
during development, and are expressed on many non-HSCs. 
We found no engraftment in both mice (Fig. 7 L), which 
indicates that the resistance to the donor HSC engraftment 
during steady-state hematopoiesis is maintained in Evi1+/ 
mice. Collectively, these data suggest that Evi1 is dispensable 
for the regulation of proliferative and differentiation capacity 
of ST-HSCs/MPPs, but is strictly required for the mainte-
nance of LT-HSC activity.
To investigate the mechanism behind the impaired HSC 
activity, we performed cell-cycle and apoptosis assays, but 
found no differences in the cell-cycle profile or apoptotic 
rates of Flk-2 CD34 LSK cells between Evi1+/+ and 
Evi1+/ mice (unpublished data). Collectively, in consider-
ation of the accelerated loss of LT-HSC activity in Evi1+/ 
mice, it is supposed that Evi1 heterozygosity directs LT-HSCs 
from self-renewal toward differentiation to generate more 
committed progenitors, which is uncoupled from cell-cycle 
progression or apoptosis.
Forced expression of Evi1 prevents HSPC differentiation  
and enhances their expansion
The findings noted above led us to hypothesize Evi1 has the 
potential to inhibit differentiation and enhance HSC self- 
renewal independent of cell-cycle progression. To clarify this, 
we adopted a gain-of-function approach, in which WT LSK 
cells were transduced with Evi1, and then incubated in serum- 
free medium. Although forced expression of Evi1 gave   
no apparent growth advantage for the first 10 d of culture, 
Evi1-transduced LSK cells subsequently manifested a mild 
but significant increase in proliferation rate (Fig. 8 A). More-
over, we found a substantial increase in the frequency of the 
remaining  LSK  fraction  in  cultured  Evi1-transduced  cells 
compared with control cells (Fig. 8 B). In parallel, the num-
ber of colonies derived from cultured Evi1-transduced LSK 
cell was drastically increased (Fig. 8 C). These results suggest 
that Evi1 activation restricts lineage differentiation and en-
hances self-renewal activity of HSPCs. Collectively, our data 
provide compelling evidence that Evi1 regulates the devel-
opmental transition from HSPCs to more committed pro-
genitors, suggesting a crucial role of Evi1 in controlling the 
balance between self-renewal and differentiation.
A recent work suggests that the longer, PR domain-
containing isoform Mds1-Evi1 (ME) deficiency alone causes 
a reduction in the number of HSCs with a loss of long-term 
repopulation capacity (Zhang et al., 2011). Because both ME 
and Evi1 are inactivated in our Evi1 KO model (Goyama 
et al., 2008), we attempted to genetically dissect the relative 
roles of ME and Evi1 in maintaining LT-HSCs. For this pur-
pose, we transduced Evi1 or ME into Evi1+/ Flk-2 CD34 
LSK cells and examined whether they could maintain stem 
cell phenotype after in vitro culture. Reintroduction of Evi1 
led to a significant increase in the proportion that remained 
in the LSK fraction, similar to observations made in Evi1+/+ 
cells (Fig. 8 D). However, retroviral transfer of ME was 
unable to normalize the frequency of the remaining LSK 
fraction (Fig. 8 D), indicating that Evi1 preferentially rescues 
Evi1+/ LT-HSC defects. Given that ME has broader effects 
Figure 8.  Forced expression of Evi1 prevents HSPC differentiation 
and promotes their expansion. (A) Proliferation of 3,000 control- or 
Evi1-transduced LSK cells cultured in serum-free medium with 20 ng/ml 
SCF and 20 ng/ml TPO for 14 d (*, P < 0.05; n = 3). (B) After 7 d of culture, 
the percentage of the remaining LSK fraction in cultured control- or Evi1-
transduced LSK cells was analyzed (*, P < 0.01; n = 3). (C) In vitro colony-
forming assay was performed to assess the numbers of CFU-GM, 
CFU-GEMM, and BFU-E colonies after 3,000 control- or Evi1-transduced 
LSK cells were cultured for 14 d (*, P < 0.005; **, P < 0.0005; n = 3).  
(D) Control-, Evi1-, or ME-transduced Evi1+/+ or Evi1+/ Flk-2 CD34  
LSK cells were cultured in medium containing 10% serum with 50 ng/ml 
SCF, 50 ng/ml TPO, 10 ng/ml IL-3, and 10 ng/ml IL-6 for 5 d, and the per-
centages of the remaining LSK fraction were analyzed (*, P < 0.05;  
**, P < 0.0005; n = 5–6). Data represent mean ± SD.JEM Vol. 208, No. 12 
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(Senyuk et al., 2007), and TGF- (Kurokawa et al., 1998). 
Together with these findings, our data strongly support a 
model in which Evi1 gene dosage is a critical determinant of 
HSC self-renewal potential.
Inappropriate expression of EVI1 confers poor prognosis 
in patients with AML (Lugthart et al., 2008; Gröschel et al., 
2010), and therefore improvement of the therapeutic out-
come of leukemia with high EVI1 expression is needed. In 
this study, we reveal that Evi1 overexpression blocks differ-
entiation and induces HSPC expansion. Our data fit with 
other studies showing that retroviral integration at the Evi1 
locus can be associated with long-term in vivo clonal domi-
nance,  occasionally  leading  to  leukemic  transformation 
(Stein  et al., 2010). The genetic events underlying AML 
pathogenesis fall into two groups: (1) mutations that enhance 
proliferation and survival of hematopoietic progenitors, or (2) 
mutations that result in impaired differentiation or aberrant 
acquisition of self-renewal properties of HSPCs (Fröhling et al., 
2005). Our data indicate that Evi1 activation can function 
as the latter mutation and confer enhanced self-renewal ca-
pacity in myeloid neoplasms. In addition, we demonstrate 
that retroviral transfer of Evi1, but not ME, can ameliorate 
the self-renewal defects in Evi1+/ HSCs, highlighting a dis-
tinct role of Evi1 in HSC self-renewal. These findings may 
explain the underlying mechanisms of the clinical observa-
tions that, irrespective of ME expression, aberrant EVI1 
expression carries an adverse prognostic value in AML (Lugthart 
et al., 2008, 2010). As it is becoming evident that leukemic 
stem cells share self-renewal machinery with normal HSCs, 
the elucidation of how Evi1 controls HSC self-renewal may 
provide  biological  insight  into  the  pathogenesis  of  Evi1- 
related leukemia.
MATERIALS AND METHODS
Generation of Evi1-IRES-GFP knock-in mice. The targeting construct 
was assembled in the plasmid vector pBluescript KS. The 5 arm of the tar-
geting vector consists of a 5.1-kb fragment of BAC clone RP24-481A14 and 
the 3 arm consists of a 3.1-kb fragment. The 5 arm contains Evi1 intron 8 
and exon 9, and the 3 arm contains intron 9, exon 10, and intron 10. Both 
arms were obtained by PCR using BAC clone RP24-481A14 as a template, 
all sequenced, and then inserted into pBluescript KS. Mouse Evi1 cDNA 
was isolated from murine embryo cDNA by PCR, with an EcoRI site at the 
5 end and a BamHI site at the 3 end, which was cloned into pBluescript 
KS. A 1.3-kb IRES-GFP cassette derived from pGCDNsam-IRES-GFP 
retroviral vector was inserted downstream of the aforementioned Evi1 frag-
ment. A polyadenylation (pA) cassette was then ligated 3 to the IRES-GFP 
cassette.  A  neomycin-positive  selection  (Neor)  cassette,  expressed  under 
control of the PGK promoter, was inserted downstream of the pA cassette. 
Both pA cassette and loxP-flanked neomycin-positive selection cassette were 
derived from DT-A/AFP(EGFP)/Neo vector (a gift from the Institute of 
Physical and Chemical Research Center for Developmental Biology, Kobe,   
Japan). The partial Evi1 cDNA-IRES-GFP-pA-loxP-neo was released intact 
by digestion with Sse8387I and cloned into a unique Sse8387I site in exon 9 
of BAC arm. A diphtheria toxin–negative selection cassette was cloned into 
pBluescript KS, 3 to the targeting construct. The targeting construct was 
linearized by SacII and transfected into TT2 ES cells by electroporation. 
Homologous recombinant clones were identified by Southern blot analysis 
of genomic DNA isolated from individual G418/FIAU-resistant ES cell col-
onies. The DNA was digested with XbaI, blotted to nylon membranes, and 
Here, we reveal that Evi1 expression specifically correlates 
with functional HSCs, whereas lack of Evi1 expression ex-
clusively identifies cells without functional HSC activity in 
both the fetal and adult hematopoietic systems. In particular, 
Evi1 expression can segregate long-term repopulating HSCs 
from  cells  without  self-renewal  potential  even  within  the 
highly subfractionated Flk-2 CD34 LSK or CD48 CD150+ 
LSK compartments. In addition, Evi1-IRES-GFP knock-in 
mice offer advantages over the conventional HSC surface 
markers, as the GFP and GFP+ subfractions of the Flk-2 
CD34 LSK or CD48 CD150+ LSK cells show a quite sim-
ilar distribution of these markers (unpublished data). Moreover, 
our findings that Evi1 specifically regulates the self-renewal 
capacity of HSCs guarantee the potential utility of Evi1 ex-
pression as an indicator of HSC activity. Therefore, the 
Evi1-IRES-GFP knock-in mouse line provides a powerful 
approach for the functional identification of self-renewing 
HSCs in vivo, thus opening a new avenue for investigating 
HSC biology.
Although functional HSCs exclusively reside in the GFP+ 
population, a proportion of GFP+ cells lack HSC function. 
As GFP protein is quite stable and degraded more slowly than 
Evi1 protein (unpublished data), these observations may re-
flect a remnant of GFP expression from cells that have just 
differentiated from GFP+ HSCs. However, it is possible that 
Evi1 expression distinguishes self-renewing ST-HSCs from 
cells with no self-renewal activity in the ST-HSC/MPP frac-
tion, as Evi1 heterozygosity affects the short-term repopulat-
ing capacity of CD34+ LSK cells.
The present findings in the hematopoietic system encour-
age us to examine the possibility that Evi1 expression serves 
as a selective marker for stem cells in other tissues or in cancer 
systems. We show that mesenchymal stem cells (MSCs), one 
of the few tissue stem cell types that have been established to 
self-renew in vivo (Morikawa et al., 2009), do not express 
Evi1.  However,  a  mouse  gene  expression  atlas  and  prior 
studies examining the expression pattern of Evi1 in various 
tissues have reported Evi1 expression in the kidney, ovary, 
uterus, intestine, stomach, lung, trachea, and nasal cavity in 
the adult mouse (Morishita et al., 1990; Perkins et al., 1991; 
Su et al., 2004). It will be interesting to determine, using 
Evi1-IRES-GFP  knock-in  mice,  whether  Evi1-expressing 
cells in these organs are enriched with tissue stem cells.
Our data suggest a unique association between Evi1 ex-
pression and HSC self-renewal activity throughout hematopoi-
etic ontogeny. Along with this stem cell–specific expression 
pattern of Evi1, the fact that the disruption of a single allele 
of Evi1 leads to a near total loss of self-renewing HSCs impli-
cates Evi1 as a central regulator in HSC self-renewal. In ad-
dition, a recent gene expression profile analysis showed that 
Evi1 binding sites are enriched in the upstream region of 
genes  expressed  selectively  in  LT-HSCs  (Forsberg  et  al., 
2010). In fact, several molecules involved in the regulation of 
HSC self-renewal have been identified as downstream targets 
or interacting proteins of Evi1, including Gata2 (Sato et al., 
2008; Yuasa et al., 2005), Pbx1 (Shimabe et al., 2009), Runx1 2414 Evi1 expression marks long-term repopulating HSCs | Kataoka et al.
In vivo transplantation assay. Transplantation assays were performed 
using the Ly5 congenic mouse system. In CRAs, lethally irradiated (9.5 Gy) 
mice were reconstituted with the indicated subsets from Evi1+/+, Evi1+/GFP, 
or Evi1+/ mice, in competition with 2 × 105 unfractionated BM cells from 
congenic mice. For second BM transplantation, BM cells (1/2 femur equiva-
lent) were obtained from recipient mice 16 wk after transplantation, and 
transplanted into a second set of lethally irradiated (9.5 Gy) mice. For recip-
rocal  transplantation  assays,  lethally  irradiated  (9.5  Gy)  or  unirradiated 
Evi1+/+ and Evi1+/ mice were transplanted with 2 × 105 WT BM cells 
without competitor cells. In non-CRAs, lethally irradiated (9.5 Gy) mice 
were reconstituted with Evi1+/+ and Evi1+/ Flk-2 CD34 LSK cells with-
out competitor cells. Reconstitution of donor-derived cells was monitored 
by staining PB cells with antibodies against Ly5.1, Ly5.2, CD3, CD4, CD8, 
B220, Mac-1, and Gr-1. When CD48+ CD150 LSK cells were trans-
planted, nonblocking anti-CD48 antibody (MRC OX78 clone) was used 
(Grassinger et al., 2010).
CFU-S assay. For CFU-S assay, 100 CD34+ LSK cells were injected into 
lethally irradiated (9.5 Gy) mice. Spleens in transplanted mice were isolated 
11 d later, and visually inspected for the presence of macroscopic colonies 
after fixation in Tellyesniczky’s solution.
RQ-PCR. Total RNA was prepared using RNeasy Mini kit (QIAGEN), 
then cDNA was synthesized with a QuantiTect Reverse Transcription kit 
(QIAGEN), and used for RQ-PCR with FastStart SYBR Green Master and 
LightCycler 480 System (Roche Applied Science) according to the manu-
facturer’s instructions. All assays were performed in triplicate and relative 
expression was normalized to the internal control GAPDH. PCR primers 
are  listed  below:  GAPDH  primer  forward,  5-CCATCACCATCTTC-
CAGGAG-3,  reverse,  5-CCTGCTTCACCACCTTCTTG-3;  Evi1 
primer  forward,  5-ATCGGAAGATCTTAGATGAGTTTTG-3,  reverse, 
5-CTTCCTACATCTGGTTGACTGG-3
Western blotting. Western blotting was performed as previously described 
(Goyama et al., 2008). In brief, mouse embryo fibroblast cells were lysed in 
TNE buffer, subjected to 7% SDS-PAGE, and transferred to a PVDF mem-
brane (Millipore). The blot was incubated with an Evi-1 (C50E12) rabbit 
monoclonal antibody (Cell Signaling Technology), and visualized by ECL 
Plus (GE Healthcare).
AGM and placental cell preparation. The day of vaginal plug observa-
tion was considered as day 0.5 postcoitum (E0.5). E10.5 AGM region or 
E12.5 placenta were carefully dissected from embryos, dissociated by incuba-
tion with 250 U/ml dispase (Godo Shusei) for 20 min and cell dissociation 
buffer (Invitrogen) for 20 min at 37°C, and followed by passages through 
18–25 G needles. Single cell suspensions were filtered through 70-µm cell 
strainer and analyzed by flow cytometry.
Endothelial cell (EC), osteoblast (OB), and MSC preparation. After 
BM cells were flushed out, bones were crushed with a pestle and mortar. 
Then bone fragments were incubated with a Collagenase/Dispase (1 mg/ml; 
Roche Applied Science) in MEM  (Wako) with 20% serum and gently agi-
tated for 90 min at 37°C. The dissociated cells were collected, and bone- 
associated  mononuclear  cells  were  isolated  with  the  use  of  density 
centrifugation with Histopaque-1083 (Sigma-Aldrich). ECs were defined as 
CD31+ TER-119 CD45, OBs were defined as CD31 TER-119 CD45 
Sca-1 ALCAM+ cells (Nakamura et al., 2010), and MSCs were defined as 
CD31 TER-119 CD45 Sca-1+ PDGFR+ cells (Morikawa et al., 2009).
Plasmid construct and retroviral transduction of LSK cells. The 
murine Evi1 or ME cDNA were inserted into a site upstream of an IRES-
EGFP cassette in the retroviral vector pGCDNsam. To produce Evi1-GFP–
expressing  retrovirus,  Plat-E  packaging  cells  were  transiently  transfected 
with retroviral constructs by using FuGENE 6 transfection reagent (Roche). 
LSK cells were purified and incubated in StemSpan SFEM medium and cyto-
kines (100 ng/ml mouse SCF and 100 ng/ml human TPO) for 24 h.   
hybridized with a 3 external Evi1 probe. Confirmatory Southern blotting 
could detect a 9.1-kb WT Evi1 allele band and a 4.1-kb correctly targeted 
Evi1-IRES-GFP allele band with this 3 probe. In EcoRV-digested genomic 
DNA from positive ES cell clones, a 5 external probe detected 10- and 
11-kb bands from the WT and targeted alleles, respectively. Next, appropri-
ately targeted ES clones were aggregated with 8-cell stage of ICR embryo, 
and  resultant  blastocysts  were  injected  into  pseudopregnant  foster  ICR 
mothers. Chimeric males, which gave germ-line transmission, were crossed 
with C57BL/6 females. Blastocyst injection and breeding of chimeras were 
performed in the Animal Center for Biomedical Research, University of 
Tokyo, Tokyo, Japan.
Mice. Evi1-IRES-GFP knock-in mice were backcrossed onto a C57BL/6 
background (Ly5.1 or Ly5.2) for at least four generations (Sankyo-Laboratory 
Service). Heterozygous Evi1 KO mice (Evi1+/ mice) were previously de-
scribed (Goyama et al., 2008). C57BL/6-Ly5.1 mice were crossed with 
Ly5.2 mice to obtain Ly5.1/Ly5.2 mice. Littermates were used as controls in 
all experiments. All animal experiments were approved by the University of 
Tokyo Ethics Committee for Animal Experiments and strictly adhered to 
the guidelines for animal experiments of the University of Tokyo.
Genotype analysis. Evi1+/ mice were genotyped by PCR as previously 
described (Goyama et al., 2008). Evi1+/GFP mice were genotyped using a 
multiplex PCR to detect both WT and Evi1-IRES-GFP alleles. Genomic 
DNA was isolated from tail biopsies and subjected to PCR using Neo and 
Evi1 primers. PCR with Neo primers detects the knock-in allele, and that 
with Evi1 primers detects the WT allele. The PCR samples were denatured 
at 94°C for 2 min, subjected to 30 cycles of amplification (94°C for 30 s, 
65°C for 1 min, and 72°C for 1 min), and followed by a final extension step 
at 72°C. PCR products were resolved by agarose gel electrophoresis. PCR 
primers are listed below: Neo primer forward, 5-AGGGGATCCGCTG-
TAAGTCT-3, reverse, 5-GCACTGACTGCTCATCCAAA-3; Evi1 
primer  forward,  5-ATGTCAGCAATTGAGAACATGG-3,  reverse, 
5-ATCCAAAGGTCCTGAGTTCAAA-3.
Flow cytometry. A list of antibodies is provided in Table S1. Stained cells 
were sorted with a FACSAriaII, and analysis was performed on LSRII (both 
from BD). A mixture of antibodies recognizing CD3, CD4, CD8, B220, 
TER-119, Mac-1, or Gr-1 was used to identify Lin+ cells. Anti-CD127 anti-
body was added to the lineage mixture, except for the analysis of CLPs. 
The data analyses were performed with FlowJo software (Tree Star). In ex-
periments with the Evi1-IRES-GFP knock-in mouse, a “fluorescence minus 
one” littermate control was analyzed in parallel to set GFP gates.
Cell-cycle analyses. For Hoechst 33342 and pyronin Y staining, cells were 
incubated with 5 ng/ml Hoechst 33342 (Invitrogen) and 25 µg/ml vera-
pamil at 37°C for 45 min. Next, pyronin Y (Sigma-Aldrich) was added to   
1 µg/ml, and the cells were incubated for an additional 15 min.
In vitro culture. For in vitro serum-free culture, cells were cultured in 
StemSpan SFEM (StemCell Technologies) supplemented with 20 ng/ml 
mouse SCF and 20 ng/ml human TPO, and subsequently subjected to flow 
cytometry or colony-forming assay at the indicated day after incubation. For 
colony-forming assay, cells were seeded in duplicate and cultured in cyto-
kine-supplemented methylcellulose medium (MethoCult GF M3434; Stem 
Cell  Technologies).  Subsequently,  colonies  were  counted  and  identified 
based on morphological examination on day 12. For in vitro differentiation, 
LSK GFP+ cells were cultured in RPMI-1640 medium (Wako) containing 
10% serum with 50 ng/ml mouse SCF, 50 ng/ml human TPO, 10 ng/ml 
mouse IL-3, and 10 ng/ml human IL-6, and subjected to flow cytometry or 
colony-forming assay after 5 d of incubation.
Single-cell  culture.  Cells  were  clone-sorted  into  96-well  plates  using 
FACS-based automated cell deposition unit and cultured in StemSpan SFEM 
supplemented with 20 ng/ml mouse SCF and 20 ng/ml human TPO. After 
14 d of culture, cell numbers in each colony were analyzed.JEM Vol. 208, No. 12 
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